ArticleDevelopmental biology2025
ShH10 viral vector for safe, efficient, and selective transduction of inner ear supporting cells.
Article in Developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hearing loss is the most prevalent type of sensory deficit in humans. Recent studies have found adeno-associated viruses (AAVs) targeting hair cells as promising vectors for inner ear gene therapy. However, targeting non-sensory cell types, which are often affected by genetic mutations causing sensorineural hearing loss, remains a challenge. In this study, we characterize the serotype ShH10, an AAV variant we show to have high tropism for supporting cells in the mouse cochlea and utricle. We demonstrate that ShH10 efficiently targets all subtypes of supporting cells along the length of cochlear duct without negatively impacting auditory function. Unlike many other potent AAV vectors tested in the inner ear, ShH10 does not spread to the central nervous system or the contralateral ear, allowing for more targeted therapy. Future studies in disease models and larger animal models will be crucial for validating the clinical potential of this serotype in correcting both genetic and acquired hearing dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.